{"filings":[{"id":2024560,"accession_number":"0001628280-26-051852","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2026-08-03T20:14:27+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q2 revenue $114.4M, exome/genome volume up 32% YoY; reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $114.4M (+11% YoY); exome/genome revenue $100.3M (+17% YoY).","Exome/genome volume 30,785 (+32% YoY); adjusted gross margin 70% (GAAP 68%).","Adjusted net income $0.4M (up $8.6M from Q1); GAAP net loss $17.7M.","Reiterates FY2026 revenue guidance $475-490M with exome/genome volume growth at least 30%.","Amended Blackstone loan: additional $50M term loan (total $150M); Blackstone bought $5M stock at $61/share; pro forma cash ~$188M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1204837,"accession_number":"0001628280-26-044806","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2026-06-23T12:35:48+00:00","items":["5.07"],"status":"ready","headline":"GeneDx stockholders elect Katherine Stueland as Class II director, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Katherine Stueland elected Class II director: 18,325,894 for, 5,893,466 withheld, 3,409,327 broker non-votes.","Ernst & Young ratified as independent auditor for FY2026: 27,466,639 for, 158,884 against.","Advisory vote on executive compensation approved: 22,705,946 for, 1,471,593 against.","Future say-on-pay frequency set at every 1 year: 23,816,121 votes for 1 year (majority)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1066556,"accession_number":"0001628280-26-043431","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2026-06-16T12:39:37+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"GeneDx names Mark Gardner as President, effective June 15, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mr. Gardner, former Quest Diagnostics SVP, will oversee lab and commercial ops, reporting to CEO Katherine Stueland.","Compensation includes $530K base salary, 65% target bonus, and $2M RSU grant vesting over four years.","Bryan Dechairo transitions to lead product, technology and innovation initiatives.","Gardner previously served as CEO of OmniSeq and held senior roles at Thermo Fisher Scientific and Life Technologies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95744,"accession_number":"0001818331-26-000039","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q1 revenue $102.3M (+17% YoY); exome/genome volume +34%; FY guidance $475-490M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $102.3M (+17% YoY); exome/genome revenue $90.6M (+27% YoY).","Exome/genome volume 27,488 (+34% YoY); adjusted gross margin 69% flat YoY.","GAAP net loss $63.3M; adjusted net loss $8.2M vs adjusted net income $9.2M in Q1 2025.","Full-year 2026 revenue guidance $475-$490M with at least 30% exome/genome volume growth; cash $171.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":102254000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109031,"accession_number":"0001818331-26-000021","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.01","1.02","2.03"],"status":"ready","headline":"GeneDx enters $100M term loan with Blackstone to repay existing credit facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$100M term loan funded Feb 27, 2026; proceeds used to repay existing Perceptive Credit term loan.","Interest rate at Term SOFR + 4.50% (1.50% floor); matures in five years.","Mandatory prepayment triggers include change of control, additional debt, asset sales.","Secured by first lien on substantially all assets; includes $50M minimum liquidity covenant.","Proceeds also for balance sheet optimization and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109030,"accession_number":"0001818331-26-000014","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q4 revenue $121M, +27% YoY; exome/genome +32%; reaffirms FY2026 guidance $540-555M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $121M (+27% YoY); exome/genome revenue $104M (+32%, or +42% ex one-time).","Q4 exome/genome volume 27,761 (+34.3% YoY); adjusted gross margin 71%.","FY2025 revenue $427.5M (+41%); adjusted net income $41.8M vs $9.4M prior year.","Reaffirmed FY2026 revenue guidance $540-555M with 33-35% exome/genome volume growth.","Cash $172.3M; Q4 operating cash flow $5.1M; issued 147,583 shares via ATM netting $21.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":427539000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109029,"accession_number":"0001818331-26-000005","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"GeneDx prelim FY2025 rev $427M (+41%); FY2026 guidance $540-555M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 exome/genome revenue ~$360M (+54% YoY); Q4 $104M (+32% YoY).","Exome/genome volume 97,271 (+30.5%) for FY2025; Q4 volume up 34.3%.","Adjusted gross margin 71% in Q4 and FY2025; cash & equivalents $172M.","FY2026 guidance: rev $540-555M, 33-35% exome/genome growth, adj gross margin ≥70%.","Expects positive adjusted net income in FY2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":427539000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125484,"accession_number":"0001818331-25-000128","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q3 2025 revenue $116.7M (+52% YoY), adjusted net income $14.7M; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $116.7M (+52% YoY); exome/genome revenue $98.9M (+65% YoY).","Adjusted gross margin expanded to 74% from 64%; adjusted net income $14.7M vs $2.0M.","Raised FY2025 revenue guidance to $425-428M; exome/genome growth 53-55% YoY.","Granted FDA Breakthrough Device Designation for ExomeDx and GenomeDx tests."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":306550000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142226,"accession_number":"0001818331-25-000121","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"GeneDx appoints Thomas Fuchs, SVP & Chief AI Officer at Lilly, as Class I director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Fuchs appointed to board effective September 17, 2025; board expands from 7 to 8 members.","Dr. Fuchs serves as SVP and Chief AI Officer at Eli Lilly, leading AI for drug discovery and clinical trials.","Initial RSU grant of $420,000 vesting over three years under non-employee director compensation policy.","Dr. Fuchs holds a doctorate in machine learning from ETH Zurich and founded Paige AI.","No transactions requiring disclosure under Item 404(a) and no arrangements with any person."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142225,"accession_number":"0001818331-25-000105","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q2 revenue $102.7M (+49% YoY); raises FY outlook to $400-415M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Exome/genome test revenue $85.9M (+69% YoY) on volume of 23,102 results (+28%).","Adjusted net income $15.0M vs. loss of $2.0M a year ago; GAAP net income $10.8M.","Adjusted gross margin expanded to 71% from 62% in Q2 2024.","Acquired Fabric Genomics for $33.2M in cash, net of cash acquired.","AAP now recommends exome/genome as first-line test for children with global developmental delay."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":189807000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160231,"accession_number":"0001818331-25-000086","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"GeneDx re-elects Casdin and Ruch as Class I directors; EY ratified as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eli D. Casdin re-elected with 16,013,641 votes for, 6,823,343 withheld.","Joshua Ruch re-elected with 17,211,360 votes for, 5,625,624 withheld.","Ratification of Ernst & Young as auditor approved: 25,459,253 for, 49,423 against, 10,809 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160230,"accession_number":"0001818331-25-000070","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q1 revenue $87.1M, exome/genome revenue up 62% YoY; raises FY 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 exome/genome revenue $71.4M (+62% YoY); total revenue $87.1M (+42% YoY).","Adjusted net income $7.7M vs loss of $8.0M a year ago; GAAP net loss $6.5M.","Announced plans to acquire Fabric Genomics; no deal value disclosed.","Raised FY 2025 revenue guidance to $360-375M; reaffirms exome/genome growth of at least 30%.","Adjusted gross margin improved to 69% from 61% YoY; cash $160.2M at quarter-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":87115000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160229,"accession_number":"0001818331-25-000057","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"GeneDx to acquire Fabric Genomics for up to $51M; expands AI genomic interpretation globally","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["GeneDx will pay $33M cash at closing for Fabric Genomics; total consideration up to $51M based on milestone achievements (2025/2026 revenue and margin targets).","Milestone payments of up to $10.5M and $7.5M can be in cash, stock (valued at $93.0318/sh), or combination.","Acquisition expected to close in Q2 2025; Fabric Genomics to operate independently post-close.","Deal enables decentralized sequencing with centralized AI interpretation, expanding NICU, newborn screening, and global markets.","GeneDx's dataset of 750K+ exomes/genomes combined with Fabric's AI platform creates barrier to entry and recurring revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178529,"accession_number":"0001818331-25-000013","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q4 revenue up 64% YoY to $95.3M; adjusted net income $16.8M; FY2025 guidance $350-360M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenues $95.3M (+64% YoY); exome/genome revenue $78.8M (+101% YoY).","Q4 adjusted gross margin 70% (vs 56% YoY); exome/genome margin >70%.","Q4 adjusted net income $16.8M (GAAP net income $5.4M); full year adjusted net income $6.7M.","FY2025 guidance: revenue $350M-$360M, exome/genome volume and revenue growth at least 30%.","Cash $142.2M at year-end; Q4 operating cash flow $12.4M including $6.8M appeal recovery."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":305450000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178528,"accession_number":"0001818331-25-000004","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"GeneDx reports prelim FY2024 revenue ≥$299M (+54% YoY), above prior guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2024 revenue at least $299M (+54% YoY), above prior guidance of $284-290M.","Q4 2024 revenue at least $92M (+59% YoY, +20% sequential); exome/genome rev $75.8M (+93% YoY).","Adjusted gross margin ≥64% FY (guidance ≥62%) and ≥68% in Q4 (up from 64% Q3).","Q4 exome/genome volume 20,676 (+32% YoY, +7% seq); expects second consecutive adjusted net income quarter and first positive operating cash flow.","Includes $6.8M discrete benefit from multi-year appeal recovery from a single payer."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":305450000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178527,"accession_number":"0001818331-25-000002","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"GeneDx appoints Bryan Dechairo as COO with $450K salary and $2.7M RSU award","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bryan Dechairo appointed COO effective Jan 2, 2025; reports to CEO Katherine Stueland.","Total annual base salary of $450,000 plus target annual bonus of 50% of base salary.","RSUs with $2.7M grant-date value vesting over 4 years; sign-on bonuses of $75K each in 2025 and 2026.","Dechairo previously CEO of Sherlock Biosciences; will oversee Product & Technology, Operations, Medical Affairs, Innovation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195202,"accession_number":"0001818331-24-000057","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx achieves Q3 2024 profitability with $1.2M adjusted net income, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $76.6M (+52% YoY); exome/genome revenue $60.0M (+77% YoY).","Adjusted net income $1.2M (first profitable quarter); GAAP net loss $8.3M.","Adjusted gross margin 64%, up from 48% YoY.","FY 2024 revenue guidance raised to $284–290M (prev. $255–265M).","Cash use improved 88% YoY to $5.0M; $117.4M cash as of Sept. 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":209810000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211463,"accession_number":"0001818331-24-000041","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q2 revenue $68.9M (+52% YoY); raises FY24 revenue guidance to $255-265M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Exome/genome test revenue $50.7M (+77% YoY), volume 18,017 (+52% YoY).","Adjusted gross margin from continuing ops 62% (up from 37% YoY).","Adjusted net loss narrowed to $2.7M, an improvement of 93% YoY.","GAAP net loss $29.2M including $13M one-time litigation charge.","Raises FY2024 revenue guidance to $255-265M; reiterates path to profitability in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":132936000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230109,"accession_number":"0001818331-24-000036","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"GeneDx stockholders elect three Class III directors and ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Emily Leproust, Keith Meister, and Richard Pfenniger Jr. elected as Class III directors with over 17M votes for each.","Auditor ratification: 23,359,773 votes for, 7,938 against, 4,319 abstentions.","All proposals on the ballot were approved at the June 20, 2024 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230108,"accession_number":"0001818331-24-000031","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"GeneDx enters $75M at-the-market equity offering agreement with TD Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may sell up to $75M of Class A common stock through TD Cowen as agent.","TD Cowen will receive up to 3.0% selling commission on gross proceeds.","ATM offering terminates upon sale of all shares or termination of agreement.","Offering made under existing shelf registration statement (File No. 333-267112)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230107,"accession_number":"0001818331-24-000021","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q1 exome/genome revenue up 96% YoY; raises FY 2024 guidance to $235-245M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from continuing ops $61.5M (+51% YoY); exome/genome revenue $44.0M (+96% YoY).","Adjusted gross margin expanded to 61% from 34% YoY; exome/genome margin above 65%.","Adjusted net loss narrowed to $8.5M (83% YoY improvement); GAAP net loss $20.2M.","Cash burn reduced 71% YoY to $17.2M; cash position $113.9M as of March 31.","Raised FY 2024 revenue guidance to $235-245M; reiterate path to profitability in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":62422000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248541,"accession_number":"0001818331-24-000006","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q4 revenue $58.1M (+27% YoY); exome/genome revenue up 68%; guides FY2024 $220-230M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue from continuing ops $58.1M (+27% YoY); exome/genome revenue $39.2M (+68% YoY).","Adjusted gross margin expanded to 56% (from 41% Q4 2022); exome/genome margin >60%.","Adjusted net loss narrowed to $17.8M, a 76% improvement YoY; cash burn reduced 51% YoY.","FY2024 revenue guidance $220-230M; reiterates path to profitability in 2025.","Exome/genome test volume 15,663 in Q4 (+99% YoY); 49,439 full year."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":202566000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248540,"accession_number":"0001818331-24-000003","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"GeneDx prelim Q4 revenue >$57M, exome/genome rev +63% YoY; cash burn -51% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 continuing ops revenue >$57M (+24% YoY); exome/genome revenue >$38M (+63% YoY).","Exome/genome test results 15,663 in Q4 (+99% YoY), now 27% of total test volume.","Cash and equivalents $131M as of Dec 31, 2023.","Q4 cash burn $33M, down 51% YoY and 21% sequentially; reiterates 2025 profitability path.","Full year 2023 continuing ops revenue expected at least $193M; exceeded revised guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":202566000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266049,"accession_number":"0001818331-23-000066","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["1.01","1.02","2.02","2.03","3.02","9.01"],"status":"ready","headline":"GeneDx Q3: revenue $53M, exome/genome up 42% YoY; cuts FY rev guidance to $187-192M; secures $75M Perceptive debt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Continuing ops revenue $50.4M; exome and genome test revenue $34M (+42% YoY). Adjusted gross margin from cont ops 48%.","Net loss $42.3M; adjusted net loss $21.2M, improved 70% YoY. Cash burn $42M, down 51% YoY.","FY2023 revenue guidance lowered to $187-192M (from $205-220M). Path to profitability in 2025 reiterated.","Entered $75M senior secured credit facility with Perceptive Advisors; initial $50M funded at SOFR+7.5%. Warrants for 800k shares at $3.17.","Enacted $40M annual cost savings plan including ~10% workforce reduction. Appointed Melanie Duquette as Chief Growth Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":145148000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283280,"accession_number":"0001818331-23-000060","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q2 2023: Exome/genome revenue up 36% YoY; cash burn down 36%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Continuing ops revenue $45.2M (+13% YoY); exome/genome rev. $28.7M (+36% YoY).","Exome/genome volume 11,900 tests (+56% YoY); total tests ~55,000.","Adj. gross margin 37% (pro forma), up from 34% in Q1; total adj. gross margin 42%.","Adj. net loss $41.8M, improved 37% YoY; cash burn $53M, improved 36% YoY.","FY2023 revenue guidance reaffirmed $205-220M; H2 cash use $70-85M; profitability target 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":91845000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283279,"accession_number":"0001818331-23-000056","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"GeneDx adopts 2023 Equity Inducement Plan, reserves 500,000 shares for new hires","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted 2023 Equity Inducement Plan on July 21, 2023, reserving 500,000 shares of Class A common stock.","Plan is substantially similar to 2021 Equity Incentive Plan but compliant with Nasdaq Rule 5635(c)(4) for inducement awards.","Only new employees or rehires after a bona fide break are eligible for grants under the plan.","Forms of award agreements for nonstatutory stock options and restricted stock units were also adopted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302708,"accession_number":"0001818331-23-000053","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"GeneDx shareholders re-elect Stueland and Ryan as directors, ratify Ernst & Young","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Katherine Stueland received 9,759,969 votes for and 2,895,500 withheld as Class II director.","Jason Ryan received 9,049,659 votes for and 3,605,810 withheld as Class II director.","Ernst & Young ratified as independent auditor with 17,113,504 votes for, 24,127 against, 3,783 abstentions.","Annual meeting held June 14, 2023; record date was May 8, 2023 with 25,590,152 shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302707,"accession_number":"0001818331-23-000046","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GeneDx regains Nasdaq minimum bid price compliance after reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified GeneDx on May 18, 2023 that it met $1.00 minimum bid for 10 consecutive days.","Company had previously received deficiency notice on Dec 28, 2022 for bid price below $1.00.","Compliance achieved after 1-for-33 reverse stock split effective May 4, 2023.","Nasdaq confirmed the matter is closed and listing continues on the Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302706,"accession_number":"0001818331-23-000041","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q1 2023 pro forma revenue $40.7M (+7% YoY); exome revenue up 22% to $22.4M; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pro forma revenue from continuing ops $40.7M, up 7% YoY; whole exome/genome test revenue $22.4M, up 22%.","Adjusted gross margin from continuing ops 34%; total company cash burn improved 31% YoY to $58.8M.","Net loss ($60.4)M; adjusted net loss ($48.9)M, improvement of 23% YoY.","Reaffirms FY2023 guidance: revenue $205-220M, cash burn $95-110M for continuing ops, profitable in 2025.","Completed $150M public offering; appointed Devin K. Schaffer as General Counsel."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":43139000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302705,"accession_number":"0001818331-23-000030","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["3.03","5.02","5.03","8.01","9.01"],"status":"ready","headline":"GeneDx announces 1-for-33 reverse stock split effective May 4, 2023; two directors not standing for re-election","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-33 ratio approved by Board on April 24, 2023; effective May 4, 2023.","No fractional shares issued; any fractional share rounded up to nearest whole share.","CUSIP changes: common stock to 81663L 200; public warrants to 81663L 127.","Directors Rachel Sherman and Dennis Charney will not stand for re-election at 2023 annual meeting; no disagreement.","Warrant exercise price adjusted from $11.50 to $379.50 per share; each warrant now exercisable for 1/33 of a share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302704,"accession_number":"0001628280-23-011808","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"GeneDx holders approve reverse split (1:10-1:50), new shares for $150M offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split authorized at ratio 1:10 to 1:50, exact ratio set by board.","Stock issuance of 22,336,624 shares approved for previously announced $150M offering.","Officer exculpation amendment to charter approved (567M for vs 33M against).","Equity incentive plan share reserve increased by 26M shares (503.9M for vs 97.2M against).","Special meeting vote totals: 599,953,892 for reverse split; 595,937,112 for stock issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302703,"accession_number":"0001818331-23-000027","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2023-04-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"GeneDx amends Executive Chairman agreement: reduced time, base salary $337,500","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason Ryan's employment as Executive Chairman extended to Dec 31, 2023.","For 2023, Ryan will work 50% time with base salary of $337,500.","Target annual performance bonus for 2023 set at 100% of base salary.","Amendment effective April 10, 2023; prior vesting End Date unchanged as Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322345,"accession_number":"0001818331-23-000021","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2023-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GeneDx Q4 revenue $61.4M (+6.2% YoY), full-year net loss $667.6M; 2023 guidance reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Combined revenue $61.4M in Q4 (+6.2% YoY); full year $234.7M (+10% YoY). Net operating loss $667.6M for FY22.","Pro forma continuing ops revenue $45.8M in Q4 (+32% YoY); full year $171.0M (+38% YoY). Adjusted gross margin 41% in Q4.","Completed $150M public offering in Jan 2023; cash position $138.3M at Dec 31, 2022.","Reiterated FY2023 guidance: revenue $205-220M, cash burn $130-145M, targeting profitability in 2025.","Whole exome sequencing volume grew 18.8% YoY in Q4; total volume up 25.8%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322344,"accession_number":"0001818331-23-000018","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"GeneDx director Dr. Michael Pellini resigns; Section 32 remains supporter after $150M financing","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Michael Pellini stepped down from the Board effective February 14, 2023.","Resignation to focus on his role as Managing Partner of Section 32, LLC.","Pellini's departure not due to any disagreement with management or the Board.","GeneDx thanked Section 32 for continued support and participation in January 2023 $150M equity financing.","Company to evaluate whether to fill the vacancy or reduce board size."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322343,"accession_number":"0001818331-23-000015","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2023-01-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"GeneDx raises ~$150M via equity offering at $0.35/share; Corvex affiliates invest $35M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 428.6M shares at $0.35 per share; net proceeds estimated at ~$143M.","Underwritten public offering of 328.6M shares; direct offering to Corvex affiliates of 100M shares.","Corvex affiliates, led by board member Keith Meister, purchase 100M shares for $35M; 22.3M shares subject to stockholder approval.","Proceeds to be used for working capital, debt repayment, and strategic investments.","Jefferies acted as underwriter and sole placement agent; special stockholder meeting called for approval of additional shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322342,"accession_number":"0001818331-23-000011","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2023-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"GeneDx presents at J.P. Morgan Healthcare Conference; full presentation details not available in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation furnished as Exhibit 99.1 for the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023.","Tagline: 'One Test: Miss Less. Discover More.' CEO Katherine Stueland presented.","No specific financial guidance or operational metrics were extractable from the truncated filing exhibit.","The presentation may contain material information, but the full content was not provided in the current filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322341,"accession_number":"0001818331-23-000006","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","5.03","9.01"],"status":"ready","headline":"GeneDx (formerly Sema4) eyes 37-40% revenue growth to ~$170-173M in 2022; guides 2023 rev $205-220M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary pro forma 2022 revenue $170-173M, up 37-40% YoY from $123.7M.","Pro forma test result volume >180,000 (+23% YoY); adjusted gross margin 38-41% (up from 34%).","2023 guidance: revenue $205-220M; cash burn for continuing ops $95-110M; targeting profitability in 2025.","Name changed to GeneDx Holdings Corp.; common stock begins trading under WGS on Jan 10, 2023.","CEO highlights combination of GeneDx and Centrellis platforms to accelerate precision medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":234694000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340389,"accession_number":"0001818331-22-000080","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2022-12-30T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Sema4 receives Nasdaq delisting notice and settles $42M payor dispute","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Sema4 that its stock bid price below $1.00 for 30 consecutive days; has 180 days to regain compliance by June 26, 2023.","Sema4 entered settlement agreement with a payor for $42M over alleged overpayments for multi-gene tests; to be paid in installments over four years.","First installment of $15M due by Dec 31, 2022; payor releases claims 91 days after first payment.","Payor also agreed to new three-year in-network participation agreement with GeneDx, LLC within 90 days.","Sema4 intends to monitor bid price and consider options to resolve noncompliance; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340388,"accession_number":"0001818331-22-000075","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Sema4 exits reproductive health, cuts 500 jobs; Q3 net loss $77.6M, focuses on pediatric/rare disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exits reproductive/women's health testing; will close Stamford lab by Q1 2023, eliminate ~500 positions (32.5% of workforce).","Q3 total revenue $83.2M (up from $43.2M YoY due to GeneDx); net loss $77.6M; adjusted net loss $76.8M.","Pediatric/rare disease volumes up 20% YoY (pro forma); revenue growth >50%; adjusted gross margin >40% in that segment.","Full-year 2022 guidance maintained: revenue $245-255M, adjusted gross margin 4-9%; aims to turn profitable by 2025.","Appointed Kevin Feeley as CFO; total cash $205.7M as of Sep 30, 2022; shares outstanding 386.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357658,"accession_number":"0001628280-22-023779","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2022-08-26T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Sema4 names Kevin Feeley CFO as interim CFO Richard Miao departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Interim CFO Richard Miao leaves Sept 2, 2022; entitled to accrued compensation.","Kevin Feeley appointed CFO effective Aug 25, 2022; also SVP of Operations and Head of GeneDx.","Feeley receives $450k base salary, 50% target bonus, and $750k equity grant.","Company files updated GeneDx combined financials for Q1 2022 and pro forma for H1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357657,"accession_number":"0001818331-22-000068","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Sema4 Q2 revenue $36.2M, net loss $85.7M; exits somatic testing, cuts 13% workforce; founder Schadt resigns","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $36.2M (or $66.3M excluding $30.1M prior-period adjustments); net loss $85.7M; adjusted net loss $72.9M.","Exiting somatic tumor testing (<1% revenue, ~$35M annual expense); eliminating ~250 positions (~13% workforce), cumulative 30% role reduction.","Founder Eric Schadt resigns as President, Chief R&D Officer, and board member; Matthew Davis (ex-Invitae) named Chief Technology & Product Officer.","FY2022 revenue guidance $245-255M; adj. gross margin 4-9% (incl. $24M prior-period adjustment); expects >$165M cash by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":90110000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357656,"accession_number":"0001818331-22-000060","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2022-07-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sema4 CAO Shawn Assad to resign; Richard Miao appointed Principal Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shawn Assad resigns as Chief Accounting Officer effective August 30, 2022; departure not related to accounting disagreements.","Richard Miao named Principal Accounting Officer, adding to his roles as Interim CFO and Deputy CFO.","Miao joined Sema4 in May 2021 as SVP of FP&A and Treasurer; previously SVP at Endeavor Group Holdings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376260,"accession_number":"0001818331-22-000053","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Sema4 CFO Isaac Ro to depart Aug. 9, 2022; Richard Miao named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Isaac Ro to leave Aug. 9, 2022; entitled to 9 months salary continuation and 12 months COBRA.","Richard Miao, SVP of FP&A and Treasurer, promoted to Deputy CFO and Interim CFO effective June 13.","Ro enters 6-month consulting agreement for advisory services with continued equity vesting.","Company reaffirms financial guidance provided May 12, 2022; search for permanent CFO engaged via Russell Reynolds.","Amendment extends Dr. Eric Schadt's 'Good Reason' notice period through April 28, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376259,"accession_number":"0001818331-22-000044","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sema4 Q1 2022: revenue $53.9M, net loss $76.9M; closes GeneDx acquisition, raises cash burn savings to $50M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $53.9M (incl. COVID-19); ex-COVID revenue $50.1M, up 4% YoY.","Adjusted gross margin 13%, up ~1,300 bps sequentially; net loss $76.9M, adjusted net loss $65.5M.","Completed GeneDx acquisition in April; $200M private placement closed with Pfizer among investors.","Reaffirms FY2022 pro forma revenue target $350M; total revenue guidance $305-315M.","Cash $315M as of March 31; expects to reduce 2022 cash burn by $50M, extending runway into 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":53941000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376258,"accession_number":"0001628280-22-011605","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2022-05-02T23:59:59+00:00","items":["1.01","2.01","3.02","5.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Sema4 closes GeneDx acquisition; Stueland becomes CEO, Schadt shifts to President","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired GeneDx for $150M cash + 80M shares upfront; up to $150M in revenue-based milestones.","Closed $200M PIPE at $4.00/share with institutional investors including Pfizer.","Katherine Stueland appointed CEO; Eric Schadt becomes President & Chief R&D Officer.","Board expanded to 11; Stueland and Richard Pfenniger elected as Class III directors.","Authorized Class A common shares increased from 380M to 1B via charter amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376257,"accession_number":"0001628280-22-010817","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2022-04-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sema4 shareholders approve GeneDx acquisition, authorize share increase to 1B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stockholders approved shares for GeneDx acquisition: 178,157,301 for, 104,365 against.","Approved PIPE investment issuance: 178,106,518 for, 153,719 against.","Approved charter amendment increasing authorized Class A common from 380M to 1B shares.","Elected three Class I directors to serve three-year terms expiring 2025.","Ratified Ernst & Young as independent auditor for fiscal year 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394612,"accession_number":"0001818331-22-000035","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2022-03-14T23:59:59+00:00","items":["2.02","4.02","9.01"],"status":"ready","headline":"Sema4 reports Q4 revenue $57.8M, restates prior-period financials due to expense classification errors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2021 revenue $57.8M (up 24% ex-COVID); full-year revenue $212.2M. Net loss $40.2M Q4, $245.4M full year.","Test volumes (ex-COVID) grew 37% YoY to 82,966; Oncology volumes up 142%, Women's Health up 33%.","Restating audited financials for 2020 and 2019, and unaudited quarters in 2021/2020, due to expense misclassification and out-of-period cost recognition.","2022 guidance: total revenue $215-225M, test volume growth >20% ex-COVID, adjusted gross margin >10%; excludes pending GeneDx acquisition.","Cash $400.6M at Dec 31, 2021; pending $200M PIPE and GeneDx acquisition expected to close Q2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394611,"accession_number":"0001818331-22-000034","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2022-03-14T23:59:59+00:00","items":["2.02","4.02","9.01"],"status":"ready","headline":"Sema4 announces non-reliance on previously issued financial statements and reports Q4 2021 results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-reliance on previously issued financial statements for years ended Dec 31, 2020 and 2019 due to expense classification errors in cost of services and selling & marketing.","Identified adjustments in cost of services recognition for Q1-Q3 2021; restated financials to be included in 2021 10-K filed March 14, 2022.","Q4 2021 test volumes (ex-COVID) up 37% YoY; total revenue $57.8M, net loss $40.2M vs $125.7M loss in prior year.","Full year 2021 revenue $212.2M up from $179.3M; net loss $245.4M vs $241.3M.","Reiterates FY2022 revenue guidance $215-225M; expects to close GeneDx acquisition by end of Q2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394610,"accession_number":"0001818331-22-000022","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2022-01-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sema4 President and COO James Coffin departs; gets $550K severance, bonus, option acceleration","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Coffin, President and COO, leaves for personal reasons effective Feb 1, 2022.","Separation agreement includes $550,000 cash severance (12 months base salary) and $180,370 bonus.","COBRA premiums reimbursed for up to 12 months; accelerated vesting of 25,425 stock options.","Extended post-termination exercise period for vested options through May 30, 2022.","CEO Eric Schadt will absorb Coffin's responsibilities; no successor named."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394609,"accession_number":"0001818331-22-000010","cik":1818331,"company_name":"GeneDx Holdings Corp.","ticker":"WGS","form_type":"8-K","filed_at":"2022-01-18T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Sema4 agrees to acquire GeneDx from OPKO for $150M cash + 80M shares; $200M PIPE at $4.00/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration: $150M cash + 80M Sema4 shares + up to $150M in revenue-based milestones.","GeneDx CEO Katherine Stueland will become Co-CEO of Sema4 post-close; Jason Ryan named Executive Chair.","PIPE of $200M (50M shares at $4.00/share) from institutional investors, including existing holders.","Closing expected in H1 2022, subject to stockholder approval, HSR, and other customary conditions.","OPKO and certain holders subject to 1-year lock-up on stock consideration; support agreements for voting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1250760000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-01-18T23:59:59+00:00|394609"}